Atrial fibrillation (AFib) ablation techniques used on individuals without cardiac abnormalities can be safely applied to adults with congenital heart disease (CHD), according to a new study in JACC: Clinical Electrophysiology. But in many cases, multiple ablation procedures are needed to boost the chances of arrhythmia-free survival.

A 6-month-old German Shepherd was the beneficiary of a successful cardiac ablation at Cornell University Hospital for Animals, one of only two centers in the U.S. that regularly offers the procedure for dogs.

Patients who developed new-onset postoperative atrial fibrillation (POAF) after coronary artery bypass graft (CABG) surgery showed a 33 percent reduced risk of thromboembolism long-term when compared to those with nonsurgical AFib, according to a study published March 28 in JAMA Cardiology.

Santa Monica, CA, March 28, 2018 — BioSig Technologies, Inc. (OTCQB: BSGM) announced that the Company has filed 510(k) application to the U.S. Food and Drug Administration (FDA) for its first product, PURE EP(TM) System.

New research presented at the American Heart Association’s Epidemiology and Prevention | Lifestyle and Cardiometabolic Health Scientific Sessions 2018 suggests individuals with depression may have an increased risk of developing atrial fibrillation (AFib).

Current clinical guidelines recommend implantable cardioverter-defibrillators (ICDs) in survivors of sudden cardiac arrest (SCA), except when the cause of the SCA is deemed reversible. But a new study in Circulation: Arrhythmia and Electrophysiology demonstrates that many of these patients gain a survival benefit from ICDs as well.

Continuous anticoagulation with apixaban during atrial fibrillation (AFib) ablation was found to be as safe as warfarin and other vitamin K antagonists (VKAs) in a randomized trial of 633 patients.

Higher alcohol consumption was linked to faster and faster heart rates in a study of more than 3,000 people attending the Munich Oktoberfest.